Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients w...

Full description

Bibliographic Details
Main Authors: Xiang Zhou, Patricia Flüchter, Katharina Nickel, Katharina Meckel, Janin Messerschmidt, David Böckle, Sebastian Knorz, Maximilian Johannes Steinhardt, Franziska Krummenast, Sophia Danhof, Hermann Einsele, K. Martin Kortüm, Leo Rasche
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
carfilzomib
extramedullary disease
multiple myeloma
relapse
refractory
Online Access:https://www.mdpi.com/2072-6694/12/4/1035

Internet

https://www.mdpi.com/2072-6694/12/4/1035

Similar Items